• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    OTR Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events (Amendment)

    5/13/22 7:16:46 AM ET
    $OTRA
    Get the next $OTRA alert in real time by email
    0001821318 false 0001821318 2022-05-10 2022-05-10 0001821318 otra:UnitsEachConsistingOfOneShareOfClassCommonStockAndOnehalfOfOneRedeemableWarrantMember 2022-05-10 2022-05-10 0001821318 us-gaap:CommonClassAMember 2022-05-10 2022-05-10 0001821318 otra:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50Member 2022-05-10 2022-05-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K/A

     

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 10, 2022

     

     

    OTR ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39708   85-2136914
    (State or other jurisdiction of   (Commission   (I.R.S. Employer
    incorporation or organization)   File Number)    Identification Number)

     

    1395 Brickell Avenue, Suite 800

    Miami, Florida
      33131
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (305) 697-9600

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant   OTRAU   The NASDAQ Stock Market LLC
    Class A Common Stock, par value $0.0001 per share   OTRA   The NASDAQ Stock Market LLC
    Warrants, each exercisable for one share of Class A Common Stock for $11.50 per share   OTRAW   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On May 10, 2022, OTR Acquisition Corp., a Delaware corporation (the “Company”), held a special meeting of stockholders (the “Special Meeting”) in connection with the proposed busines combination (the “Business Combination”) contemplated by the Business Combination Agreement, dated as of January 31, 2022 (as amended or restated from time to time, the “Business Combination Agreement”) by and among the Company, Comera Life Sciences Holdings, Inc. (“Holdco”), Comera Life Sciences, Inc. (“Comera”), CLS Sub Merger 1 Corp. (“Comera Merger Sub”) and CLS Sub Merger 2 Corp. (“OTR Merger Sub”), as described in the definitive proxy statement filed by the Company with the Securities and Exchange Commission on April 15, 2022 (the “Proxy Statement”). Present at the Special Meeting were holders of 7,128,767 shares of the Company’s Class A common stock, par value $0.0001 per share (“Class A Common Stock”) and 2,611,838 shares of the Company’s Class B common stock, par value $0.0001 per share (“Class B Common Stock” and together with the Class A Common Stock, “Common Stock”), in person or by proxy, representing 74.41% of the voting power of the Company’s Common Stock issued and outstanding as of April 11, 2022, the record date for the Special Meeting (the “Record Date”), and constituting a quorum for the transaction of business. As of the Record Date, there were 13,242,017 shares of Common Stock issued and outstanding.

     

    At the Special Meeting, the Company’s stockholders approved the Business Combination Proposal, the Charter Amendment Proposal and the Equity Incentive Award Plan Proposal, in each case as defined and described in greater detail in the Proxy Statement. The Adjournment Proposal, as defined and described in greater detail in the Proxy Statement, was not presented to the Company’s stockholders as the Business Combination Proposal, the Charter Amendment Proposal and the Equity Incentive Award Plan Proposal each received a sufficient number of votes for approval.

     

    Set forth below are the final voting results for the Business Combination Proposal, the Charter Amendment Proposal and the Equity Incentive Award Plan Proposal:

     

    The Business Combination Proposal  

     

    A proposal to approve and adopt the Business Combination Agreement. The voting results of the shares of Common Stock were as follows:

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    9,675,143  177,849  0  0

     

    The Charter Amendment Proposal  

     

    The following three (3) separate governance proposals (the “Governance Proposals”) relating to the following material differences between the Company’s current amended and restated certificate of incorporation and the amended and restated certificate of incorporation of Holdco were approved on a non-binding advisory basis. The voting results of the shares of Common Stock for each of the Governance Proposals were as follows:

     

    (a)Advisory Governance Proposal 2A – to increase the number of authorized shares of Common Stock from 110,000,000 to 150,000,000;

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    9,675,142  177,850  0  0

     

     

     

     

    (b)Advisory Governance Proposal 2B – to change the number of classes of directors from two classes to three classes; and

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    8,552,365  1,300,627  0  0

     

    (c)Advisory Governance Proposal 2C – to remove the renouncement of corporate opportunity doctrine.

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    9,233,522  611,970  7,500  0

     

    The Equity Incentive Award Plan Proposal

     

    The proposal to approve the adoption of the equity incentive award plan established to be effective after the closing of the Business Combination was approved. The voting results of the shares of Common Stock were as follows:

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    9,666,642  178,850  7,500  0

     

    Redemption of Class A Common Stock

     

    As of May 11, 2022, holders of an aggregate of 10,279,363 shares of Class A Common Stock had exercised their right to redeem their shares. Subsequently, the Company has been made aware that certain holders of Class A Common Stock may request to change their election to have their shares redeemed, which the Company may allow.  There can be no assurance, however, that such holders will request to change their election to redeem their shares or that the final number of shares redeemed will decrease.

     

    Item 8.01 Other Events

     

    The Company anticipates that the closing of the Business Combination will occur on or before May 19, 2022, subject to the satisfaction or waiver of all of the requirements to closing.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: May 13, 2022

     

      OTR ACQUISITION CORP.
       
      By: /s/ Nicholas J. Singer
        Name: Nicholas J. Singer
        Title: Chief Executive Officer

     

     

     

    Get the next $OTRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTRA
    SEC Filings

    View All

    SEC Form 15-12B filed by OTR Acquisition Corp.

    15-12B - OTR Acquisition Corp. (0001821318) (Filer)

    5/31/22 8:00:30 AM ET
    $OTRA

    OTR Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OTR Acquisition Corp. (0001821318) (Filer)

    5/24/22 4:31:11 PM ET
    $OTRA

    SEC Form 25-NSE filed by OTR Acquisition Corp.

    25-NSE - OTR Acquisition Corp. (0001821318) (Subject)

    5/19/22 4:06:33 PM ET
    $OTRA

    $OTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics

    – Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb

    5/20/22 8:00:00 AM ET
    $OTRA
    $OTRAU
    Business Services
    Finance

    Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation

    Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c

    5/9/22 8:00:00 AM ET
    $OTRA

    Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo

    Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202

    4/27/22 8:00:00 AM ET
    $OTRA

    $OTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Gray Glenn Evan converted options into 22,123 shares and disposed of 100,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:37:26 PM ET
    $OTRA

    SEC Form 4: Otr Acquisition Sponsor Llc converted options into 1,305,918 shares and disposed of 1,305,918 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:35:50 PM ET
    $OTRA

    SEC Form 4: Besner Nadav converted options into 5,000 shares and disposed of 5,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:36:27 PM ET
    $OTRA

    $OTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    1/24/23 9:57:09 AM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/20/22 4:37:55 PM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/10/22 4:19:44 PM ET
    $OTRA